InvestorsHub Logo
Followers 126
Posts 5297
Boards Moderated 1
Alias Born 04/26/2001

Re: JellyDonut post# 4986

Wednesday, 08/26/2015 10:03:50 AM

Wednesday, August 26, 2015 10:03:50 AM

Post# of 5675
Do you even have a clue as to what is going on?

RE: Trappsol is being used and is working. Vtesse's drug is not.

Small Biotech Gets Rights to Rare Disease Drug

NIH Licenses Cyclodextrin Rights to Vtesse, Which Will Take On Development for NPC Treatment

The article states: "cyclodextrin used in the NIH trial is made by Janssen Research & Development, a unit of Johnson & Johnson."

and


The NIH has invested heavily in the cyclodextrin project, spending an estimated $15 million to $20 million doing toxicology studies, regulatory work with the FDA, and other aspects of drug development.

A Janssen spokesman said the company doesn’t have a separate research and development team for rare diseases, and has focused its efforts on developing drugs in areas where it has scientific expertise, including oncology and immunology. Janssen will continue to supply the drug free to Vtesse for research and to families who have received FDA permission, he said.

_____

HTF can you say that VTESSE's drug is not being used when the NIH (do you even know what NIH that stands for?) is the one spending millions on the cyclodextrin??? ... and the article just told you that the NIH licensed the rights of the cyclodextrins they spent millions on to VTESSE.

HOW IS THAT NOT CLEAR TO YOU????????




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTH News